Right-to-Try Bill Passes the Senate

The legislation removes restrictions for seriously ill patients to access experimental treatments that have not received FDA approval.

Written byCatherine Offord
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

PIXABAY, VAL-GB Abill allowing seriously ill patients to obtain access to experimental, unapproved treatments passed the US Senate in a unanimous vote on Thursday (August 3). The legislation, known as the Right to Try Act, expands on similar laws already passed in 37 states, and eliminates the requirement for patients to obtain permission from the US Food and Drug Administration (FDA) to purchase treatments that are still undergoing evaluation.

“These are real people facing their mortality with no hope,” Senator Ron Johnson (R-WI), who sponsored the bill, said from the Senate floor. “This right-to-try piece of legislation will give those individuals and their family hope.”

The current bill is an updated version of legislation that Johnson proposed in January, and was passed as part of a deal after the Senator threatened to delay a critical FDA funding reauthorization bill unless a vote took place on the right-to-try legislation. Unlike the original version, the now-passed legislation requires that safety problems occurring in right-to-try situations are reported to the FDA. It also prevents drug companies from charging patients more than the production cost for the treatment itself.

Critics argue that the measure is unnecessary, as the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • After undergraduate research with spiders at the University of Oxford and graduate research with ants at Princeton University, Catherine left arthropods and academia to become a science journalist. She has worked in various guises at The Scientist since 2016. As Senior Editor, she wrote articles for the online and print publications, and edited the magazine’s Notebook, Careers, and Bio Business sections. She reports on subjects ranging from cellular and molecular biology to research misconduct and science policy. Find more of her work at her website.

    View Full Profile
Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies